


Supplementary Table 1. Expression levels of the sputum miRNAs and plasma miRNAs in NSCLC patients versus cancer-free controls of the training cohort

	Mean (SEM) of miRNA level in NSCLC patients	Mean (SEM) of miRNA level in controls	P-value
Sputum miR-21-5p	59.23 (5.48)	7.39 (1.26)	< 0.001
Sputum miR-210-3p	69.26 (6.12)	6.08 (0.45)	< 0.001
Plasma miR-21-5p	23.27 (5.53)	8.12 (3.39)	< 0.001
Plasma miR-210-3p	12.49 (3.73)	4.49 (1.27)	< 0.001
Plasma miR-486-5p	122.65 (29.67)	78.36 (10.05)	< 0.001



Supplementary Fig.1.

The receiver-operator characteristic (ROC) curve of sputum and plasma miRNA biomarkers for lung cancer diagnosis. Two sputum miRNAs (miRs-21-5p and 210-3p) and one plasma miRNA (miRNA-31-5p) were selected as the best ones and incorporated into an algorithm: $P = \frac{e^x}{1 + e^x}$, where $x = 6.62 + 1.84 \times \log(\text{miR-21-5p}) - 2.6 \times \log(\text{miR-21-3p}) - 2.36 \times \log(\text{miR-31-5p})$. The algorithm produced the area under the ROC (AUC) of 0.91 for distinguishing lung cancer cases from controls.